SNU-5 In Vitro High Content Screening (HCS) Assay

This assay is to provide SNU-5-based In Vitro High Content Screening (HCS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

SNU-5

Human

SNU-5 was line derived in 1987 by J. Park and associates from ascites of a patient with poorly differentiated carcinoma of the stomach. The patient had previously received chemotherapy including 5-fluorouracil, doxorubicin and mitomycin-C.
Derived from metastatic site, ascites

Gastric Carcinoma

Oncology

In Vitro High Content Screening (HCS) Assay

SNU-5-cell based In Vitro High Content Screening (HCS) Assay

HCS is one of the latest techniques used in cancer drug discovery programs. Unlike traditional HTS platforms, HCS provides more visual information about the experiment being conducted. HCS is a very powerful tool for multivariate and quantitative data analysis. Cellbased HCS systems have also gained much attention in biological research and cancer drug discovery programs.

High-throughput Screening, High Content Screening and Reporter Gene Assays